Lyell Immunopharma, Inc. (LYEL) Financial Statements
Lyell Immunopharma, Inc. (LYEL) reported trailing twelve-month revenue of $27000 (down 55.0% year on year) and net income of -$248.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$134.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LYELLyell Immunopharma, Inc.Follow LYEL — free
—
Price chart with a free account
- Market cap
- 230.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.01 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research & development | 0.14 | 0.16 | 0.18 | 0.17 | 0.16 | 0.16 | |
| Operating income | -0.21 | -0.19 | -0.25 | -0.36 | -0.27 | -0.26 | |
| Pre-tax income | -0.25 | -0.18 | -0.23 | -0.34 | -0.27 | -0.25 | |
| Income tax | — | — | — | — | 0.00 | — | |
| Net income | -0.25 | -0.18 | -0.23 | -0.34 | -0.27 | -0.25 | |
| Diluted EPS ($) | -36.80 | -14.80 | -18.70 | -26.23 | -16.06 | -10.64 | |
| Diluted shares (bn) | 0.007 | 0.012 | 0.013 | 0.013 | 0.017 | — |
USD billions · SEC XBRL
Lyell Immunopharma, Inc. — questions
- What is Lyell Immunopharma, Inc.'s revenue?
- $27000 over the twelve months to 2026-06-30, down 55.0% year on year, from its 10-Q and 10-K filings.
- What is Lyell Immunopharma, Inc.'s net income?
- -$248.5M over the twelve months to 2026-06-30.
- What is Lyell Immunopharma, Inc.'s free cash flow?
- -$134.0M over the twelve months to 2026-06-30.
- What are Lyell Immunopharma, Inc.'s diluted earnings per share?
- $-10.64 over the twelve months to 2026-06-30.
Every figure on this page comes from Lyell Immunopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.